|
Sign In to gain access to subscriptions and/or personal tools.
|
Clinical and Applied Thrombosis/Hemostasis, Vol. 12, No. 4,
389-396 (2006)
DOI: 10.1177/1076029606293692
Secondary Prevention of Venous Thromboembolic Events in Patients With Active Cancer: Enoxaparin Alone Versus Initial Enoxaparin Followed by Warfarin for a 180-Day Period
Steven R. Deitcher, MD
Section of Hematology and Coagulation Medicine, The Cleveland Clinic Foundation, Cleveland, Ohio, sdeitcher{at}nuvelo.com
Craig M. Kessler, MD
Lombardi Cancer Center, Georgetown University Medical Center, Washington, District of Columbia
Geno Merli, MD
Division of General Internal Medicine, Thomas Jefferson University, Philadelphia, Pennsylvania
James R. Rigas, MD
Division of Hematology and Medical Oncology, Dartmouth Medical School, Lebanon, New Hampshire
Roger M. Lyons, MD
U.S. Oncology, San Antonio, Texas
Jawed Fareed, PhD
Loyola University Medical Center, Maywood, Illinois
This study evaluated enoxaparin alone versus initial enoxaparin followed by warfarin in secondary prevention of venous thromboembolic events in adults with active malignancy. Cancer patients (n = 122) with acute symptomatic venous thromboembolic events were randomly allocated to receive subcutaneous enoxaparin 1.0 mg/kg every 12 hours for 5 days, followed by 1.0 mg/kg daily (group 1a) or 1.5 mg/kg daily (group 1b) for 175 days, or subcutaneous enoxaparin 1.0 mg/kg every 12 hours for at least 5 days and until a stable international normalized ratio of 2 to 3 was achieved on oral warfarin begun on day 2 and continued to day 180 (group 2). There were no significant differences in major and minor bleeding rates between treatment groups. No bleeding events were intracranial or fatal. Enoxaparin treatment was feasible, generally well tolerated, and effective for a 180-day period in the secondary prevention of venous thromboembolic events in patients with active malignancy.
Key Words: Enoxaparin • Deep venous thrombosis • Malignancy
References
- Deitcher SR: Cancer-related deep venous thrombosis. Clinical importance, treatment challenges, and management strategies. Semin Thromb Haemost. 2003; 29: 247-258.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
- Luzzatto G, Schafer AI. The prethrombotic state in cancer. Semin Oncol. 1990; 17: 147-159.[ISI][Medline]
[Order article via Infotrieve]
- Bona RD, Sivjee KY, Hickey AD, Wallace DM, Wajcs SB. The efficacy and safety of oral anticoagulation in patients with cancer. Thromb Haemost. 1995; 74: 1055-1058.[ISI][Medline]
[Order article via Infotrieve]
- Levine M, Gent M, Hirsch J, Leclerc J, Anderson D, Weitz J, Ginsberg J, Turpie AG, Demers C, Kovacs M. A comparison of low-molecular-weight heparin administered primarily at home with unfractionated heparin administered in the hospital for proximal deep-vein thrombosis. N Engl J Med. 1996; 334: 677-681.[Abstract/Free Full Text]
- Merli G, Spiro TE, Olsson C-G, et al; Enoxaparin Clinical Trial Group. Subcutaneous enoxaparin once or twice daily compared with intravenous unfractionated heparin for treatment of venous thromboembolic disease. Ann Intern Med. 2001; 134: 191-202.[Abstract/Free Full Text]
- Weitz JI. Low-molecular-weight heparins. N Engl J Med. 1997; 337: 688-698.[Free Full Text]
- Warkentin TE, Levine MN, Hirsh J, et al. Heparin-induced thrombocytopenia in patients treated with low-molecular-weight heparin or unfractionated heparin. N Engl J Med. 1995; 332: 1330-1335.[Abstract/Free Full Text]
- Oken, MM, Creech, RH, Tormey, DC, et al. Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 1982; 5: 649-655.[ISI][Medline]
[Order article via Infotrieve]
- Hyers TM, Agnelli A, Hull RD, et al. Antithrombotic therapy for venous thromboembolic disease. Chest. 2001; 119(suppl): 176S-193S.[Free Full Text]
- Meyer G, Marjanovic Z, Valcke J, et al. Comparison of low-molecular-weight heparin and warfarin for the secondary prevention of venous thromboembolism in patients with cancer: a randomized controlled study. Arch Intern Med. 2002; 162: 1729-1735.[Abstract/Free Full Text]
- Lee AY, Levine MN, Baker RI, et al; Randomized Comparison of Low-Molecular-Weight Heparin versus Oral Anticoagulant Therapy for the Prevention of Recurrent Venous Thromboembolism in Patients with Cancer (CLOT) Investigators. Low-molecular-weight heparin versus a coumarin for the prevention of recurrent venous thromboembolism in patients with cancer. N Engl J Med. 2003; 349: 146-153.[Abstract/Free Full Text]
- Hull RD, Pineo GF, Mah AF, Brant RF, for the LITE study Investigators. A randomized trial evaluating long-term low-molecular-weight heparin therapy for three months versus intravenous heparin followed by warfarin sodium. Blood. 2002; 100: 148a-148a (abstract 556).
- Rosendaal FR. Risk factors for venous thrombosis: prevalence, risk, and interaction. Semin Hematol. 1997; 34: 171-187[ISI][Medline]
[Order article via Infotrieve]
- Deitcher SR, Choueiri T, Srkalovic G, Hussein MA. Acquired activated protein C resistance in myeloma patients with venous thromboembolic events. Br J Haematol. 2003; 123: 959-959.[CrossRef][ISI][Medline]
[Order article via Infotrieve]
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati What's this?
This article has been cited by other articles:
|
|
|
|
 
A. Falanga, A. Y. Y. Lee, M. B. Streiff, and G. H. Lyman
Anticoagulation in the Treatment of Venous Thromboembolism in Patients with Cancer
ASCO Educational Book,
January 1, 2008;
2008(1):
258 - 268.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
|
|
|
G. H. Lyman, A. A. Khorana, A. Falanga, D. Clarke-Pearson, C. Flowers, M. Jahanzeb, A. Kakkar, N. M. Kuderer, M. N. Levine, H. Liebman, et al.
American Society of Clinical Oncology Guideline: Recommendations for Venous Thromboembolism Prophylaxis and Treatment in Patients With Cancer
J. Clin. Oncol.,
December 1, 2007;
25(34):
5490 - 5505.
[Abstract]
[Full Text]
[PDF]
|
|
|
|
